A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
TerminatedPhase 3Results postedLast updated 16 April 2020
What this trial tests
Phase 3 trial testing LV305 in Synovial Sarcoma in 1 participant. Terminated before completion.
12 and older, any sex, with Synovial Sarcoma or Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE)Secondary· From randomization to investigator-determined date of disease progression or death, assessed up to approximately 2 months.
Safety will be assessed primarily based on reported adverse events (AEs), Medical Events of Interest (MEOIs), laboratory values, and concomitant medications reported from initiation of treatment with CMB305 or placebo.
Group
Value
95% CI
CMB305
1
Number of Participants Who Discontinued Study Treatment Due to an AESecondary· Up to approximately 2 months
The number of all participants who discontinued study treatment due to an AE is presented.
Group
Value
95% CI
CMB305
0
Sponsor's own description
To assess if the CMB305 vaccine regimen may help the body's immune system to slow or stop the growth of synovial sarcoma tumor and improve survival.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05492682 — START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
· Phase 1
· active not recruiting
NCT04995003 — HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
· Phase 1
· recruiting
NCT04420975 — Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
· Phase 1
· active not recruiting
Other Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) trials
Trials by the same sponsor.
NCT02501473 — Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymp
· Phase 1, PHASE2
· terminated
NCT02609984 — Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma
· Phase 2
· terminated
NCT02387125 — Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
· Phase 1
· terminated
NCT02122861 — Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
· Phase 1
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Last refreshed: 16 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03520959.